Crown Bioscience collaborates with HanX Biopharmaceutical, enabling the progression of HX009 to clinical trials for the treatment of lymphoma. The study demonstrates the efficacy of HX009 in target...
CrownBio’s ALL and AML patient-derived xenograft (PDX) models of different leukemia subtypes are unique in the commercial world, in that they are validated, stable models with typical leukemia symp...